$LIPO News
Last published 1y ago
- 1y agoLIPOLipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen PlanusGlobeNewswireAll 27 patients completed treatment with no serious adverse events, underscoring a favorable safety profileStatistically significant improvements achieved across all efficacy endpoints at the 4-week timepointPreparing to initiate a piv
- 1y agoLIPOLipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic TechnologyGlobeNewswirePITTSBURGH, June 17, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with
- 1y agoLIPOLipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical DevelopmentGlobeNewswirePITTSBURGH, June 04, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with
- 1y agoLIPOLipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International MeetingGlobeNewswireStatistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented Presentation scheduled for Thursday, May 15, 2025, at 11:36 a.m. PT PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) --
- 1y agoLIPOLipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on "Global Transformation in Oral Medicine"GlobeNewswireJoint meeting to be held in Las Vegas, May 14-17 Presentation will be delivered by Dr. Alessandro Villa of Miami Cancer Institute Topline study results demonstrate clinically meaningful improvements in OLP Visible
- 1y agoLIPOLipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025GlobeNewswireSecond Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral Rinse Phase 2a Study Now Fully Enrolled Across All Three Dose Cohorts Advancing Toward Phase 2b
- 1y agoLIPOLipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen PlanusGlobeNewswirePITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies for unmet
- 1y agoLIPOLipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse PodcastGlobeNewswirePITTSBURGH, March 31, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our," "us," or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant
- 1y agoHCTILIPOSpartan Capital Securities, LLC Announces Key February TransactionsGlobeNewswireNew York, NY, March 07, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a full-service investment banking firm, is pleased to announce a series of strategic transactions completed in February 2025,
- 1y agoLIPOSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private PlacementGlobeNewswireNew York, NY, March 04, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the successful completion of a $3,788,000 private placement for Lipella
- 1y agoLIPOLipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen PlanusGlobeNewswireLP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key Metrics Findings Highlight Favorable Safety Profile and Tolerability of Twice-Daily Oral Rinse
- 1y agoLIPOLipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen PlanusGlobeNewswirePITTSBURGH, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical
- 1y agoLIPOSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private PlacementGlobeNewswireNew York, NY, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the successful completion of two private placements for Lipella
- 1y agoEFSHLIPOSpartan Capital Securities, LLC Caps Off a Remarkable Year with Key December TransactionsGlobeNewswireNew York, NY, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a full-service investment banking firm, is proud to announce a series of notable transactions completed in December 2024, further
- 1y agoLIPOSpartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private PlacementGlobeNewswireNew York, NY, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities LLC, a premier investment banking firm, is pleased to announce the successful completion of a private placement for Lipella Pharmaceuticals
- 1y agoLIPOLipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen PlanusGlobeNewswirePITTSBURGH, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO), a clinical-stage biotechnology company dedicated to addressing serious diseases with significant unmet needs, today announced
- 1y agoLIPOLipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose GroupGlobeNewswirePITTSBURGH, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on innovative therapies for serious diseases with
- 1y agoLIPOLipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery PlatformGlobeNewswirePITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs,
- 2y agoLIPOLipella Pharmaceuticals Announces 1-for-8 Reverse Stock SplitGlobeNewswirePITTSBURGH, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) (the "Company," "our" or "us"), a clinical-stage biotechnology company focused on developing innovative therapies for serious
- 2y agoLIPOLipella Pharmaceuticals to Present at 2024 Spartan Capital Investor ConferenceGlobeNewswirePITTSBURGH, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on addressing serious diseases with significant
- 2y agoLIPOLipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery PlatformGlobeNewswirePatent application covers key technology innovations for delivering therapeutic agentsProprietary technology enables precise delivery to improve safety and efficacy in oncology, cancer survivorship and
- 2y agoLIPOLipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual SummitGlobeNewswirePITTSBURGH, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on addressing serious diseases with significant
- 2y agoLIPOPRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness MonthGlobeNewswireNEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive Q&A with Dr. Michael Chancellor, Co-founder and Chief Medical Officer of Lipella Pharmaceuticals, Inc. (NASDAQ:LIPO). In this
- 2y agoLIPOLipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen PlanusGlobeNewswirePITTSBURGH, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on addressing serious diseases with significant
- 2y agoLIPOLipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New YorkGlobeNewswirePITTSBURGH, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (NASDAQ:LIPO) ("Lipella") will participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York City at the Lotte New
- 2y agoLIPOLipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus ResearchGlobeNewswireAffecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouthNo FDA-approved therapy currently exists for OLPPatient registry and OLP study information is now
- 2y agoLIPOLipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ ConferenceGlobeNewswireLP-20 contrast agent designed to diagnose interstitial cystitis and detect bladder cancerNovel MRI contrast agent, which received support from National Institute of Diabetes and Digestive and Kidney Diseases5th
- 2y agoLIPOLipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical TrialGlobeNewswirePITTSBURGH, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our," "us," "we" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with
- 2y agoLIPOLipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq RulesGlobeNewswirePITTSBURGH, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. ("Lipella" or the "Company") (NASDAQ:LIPO), a clinical-stage biotechnology company addressing serious diseases with significant unmet need,
- 2y agoLIPOLipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq RulesGlobeNewswirePITTSBURGH, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. ("Lipella" or the "Company") (NASDAQ:LIPO), a clinical-stage biotechnology company addressing serious diseases with significant unmet
- 2y agoLIPOLipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First PatientsGlobeNewswirePITTSBURGH, July 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need,
- 2y agoLIPOLipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen PlanusGlobeNewswireClinical testing of LP-310 expected to commence in mid-2024 Patient recruitment is underway for Phase 2a multicenter, dose-ranging study PITTSBURGH, May 31, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals
- 2y agoLIPOLipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswirePITTSBURGH, May 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant
- 2y agoLIPOFollowing Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2bGlobeNewswirePITTSBURGH, May 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company, announced today the receipt of U.S. Food & Drug
- 2y agoLIPOLipella Pharmaceuticals Expands its Advisory Board to Include Oncology ExpertiseGlobeNewswirePITTSBURGH, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company, today announced the expansion of its Scientific
- 2y agoLIPOLipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024GlobeNewswirePITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our", "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant
- 2y agoLIPOLipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic CystitisGlobeNewswirePITTSBURGH, April 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with
- 2y agoLIPOLipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical PipelineGlobeNewswirePITTSBURGH, March 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant
- 2y agoLIPOLipella Pharmaceuticals to Present at PropThink Digital Investor ConferenceGlobeNewswirePITTSBURGH, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc., (NASDAQ:LIPO) ("Lipella," "our," "us" or the "Company"), a pioneering, clinical-stage pharmaceutical company,
- 2y agoLIPOLipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones AccomplishedGlobeNewswirePITTSBURGH, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc., (NASDAQ:LIPO) ("Lipella," "our," "us" or the "Company"), a pioneering, clinical-stage pharmaceutical company,
- 3y agoLIPOFDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host DiseasePR NewswireLipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical stage pharmaceutical company addressing serious diseases with significant unmet need based in ...
- 3y agoONCYCRDFLLYABBV+1Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely IncreasingPR NewswirePancreatic ductal adenocarcinoma (PDAC) is a fatal malignancy of both the digestive system and endocrine system with disappointing prognoses. The...
- 3y agoLIPOLipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo ConferenceACCESS NewswirePITTSBURGH, PA / ACCESSWIRE / October 23, 2023 / Lipella Pharmaceuticals Inc. , a clinical-stage biotechnology company addressing
- 3y agoLIPOLipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and NephrologyPR NewswireArticle highlights results from successful Phase 2a clinical trial for lead candidate, LP-10 Lipella expects to initiate Phase 2b clinical trial in LP-10 in early 2024 PITTSBURGH, Pa., Sept. 21, 2023 /PRNewswire/ --
- 3y agoLIPOLipella Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate UpdatePR NewswireSuccessful top line results from Phase 2a clinical trial for lead candidate LP-10 Oral Health Scientific Advisory Board established to focus on development of LP-310 for oral lichen planus Late-breaking presentation of
- 3y agoLIPOLipella Pharmaceuticals Delivers Late-Breaking Presentation at the American Urological Association Annual MeetingPR NewswirePresentation Focused on Positive Results from Recent Phase 2a Study PITTSBURGH, May 1, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the
- 3y agoLIPOLipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSitePR NewswireLipella to collaborate in anticipation of forthcoming Investigational New Drug (IND) application LP-10 is a promising potential treatment for hemorrhagic cystitis that has received Orphan Drug Designation from the
- 3y agoLIPOLipella Pharmaceuticals Doses First Patient in Human Study of Innovative Contrast AgentPR NewswireLipella awarded $1.35m grant in 2022 for development of intravesical contrast-enhanced magnetic resonance imaging (ICE-MRI) technology. PITTSBURGH, April 5, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO)
- 3y agoLIPOLipella Provides Business Update and Reports 2022 Financial ResultsPR NewswireCompany Successfully Completes Phase 2a Clinical Trial Fourth Quarter or Full Year Highlights• Appointed Douglas Johnston as CFO in November 2022 • Successfully completed Initial Public Offering, attained NASDAQ CM
- 3y agoLIPOLipella Pharmaceuticals Successfully Completes Phase 2a Clinical Trial; Announces Late-Breaking Presentation at the Annual Meeting of the American Urological AssociationPR NewswirePITTSBURGH, March 16, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company") today announced the successful completion of a Phase